Lung AI vs Reveal LINQ

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung AI

by Exo

Reveal LINQ

by Medtronic

AI Verdict

Tool A (Lung AI) is an AI-powered handheld ultrasound device focused on real-time cardiac and lung imaging and diagnosis, suitable for immediate point-of-care decisions. Tool B (Reveal LINQ) is an implantable cardiac monitor that continuously records ECG over extended periods, utilizing AI for long-term arrhythmia detection and diagnosis. While both tools leverage AI in cardiology, their deployment, duration of monitoring, and primary diagnostic focus differ significantly, making them adjacent rather than direct competitors.

Choose Lung AI if…

Choose Lung AI if you need immediate, point-of-care diagnostic capabilities for cardiac and lung conditions. This handheld ultrasound device with integrated AI is ideal for emergency medicine or pulmonology settings where real-time decisions are critical, allowing for rapid detection of issues like pleural effusion or consolidation without internet connectivity.

View Lung AI →

Choose Reveal LINQ if…

Choose Reveal LINQ if you require long-term, continuous cardiac monitoring for up to three years to diagnose intermittent arrhythmias or investigate unexplained syncope or cryptogenic stroke. This implantable cardiac monitor is best suited for patients needing extended, discreet ECG recording with AI-powered accuracy to reduce false alerts, and it offers wireless data transmission for remote clinician review.

View Reveal LINQ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung AI	Reveal LINQ
Pricing	Contact for pricing	Unknown
Deployment	On-device (integrated with Exo Iris handheld ultrasound device)	The Reveal LINQ ICM is an implantable device placed just beneath the skin in the upper left side of the chest through a small incision. The system includes a MyCareLink™ Monitor, a bedside unit that collects data from the ICM and sends it to the doctor. The Reveal LINQ Mobile Manager app, used by healthcare professionals, is downloaded to an iPad or Android tablet and paired via Bluetooth to a Medtronic patient connector, which communicates with the ICMs.
BAA Available	Yes AI-estimated	Unknown
FDA Status	1 AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool A (Exo Lung AI) is integrated into a handheld ultrasound device designed for point-of-care use, making it highly accessible and user-friendly for a broad range of clinicians, including those with limited ultrasound experience. Its real-time feedback and guided image capture features simplify the process of obtaining and interpreting images. Tool B (Reveal LINQ) is an implantable device, which, while convenient for long-term monitoring, involves a medical procedure for insertion and relies on a separate bedside monitor and mobile app for data transmission and clinician management, adding layers of interaction for both patients and clinicians.

Clinical Value

Lung AI

Tool A (Exo Lung AI) offers real-time AI-powered detection of multiple critical conditions like pleural effusion, consolidation/atelectasis, and various cardiac conditions, providing immediate diagnostic insights at the point of care. Clinical studies have shown it improves diagnostic accuracy for clinicians, particularly less experienced users. Tool B (Reveal LINQ) provides continuous, long-term ECG monitoring for arrhythmia detection, which is valuable for diagnosing infrequent cardiac events, but its diagnostic utility is focused on a narrower set of conditions and requires post-hoc analysis of recorded data.

Pricing & Value

Tie

Both tools require contacting the vendor for pricing, indicating a lack of public transparency. While the Reveal LINQ's insertion procedure can be performed in a less resource-intensive setting, potentially reducing costs, the overall value proposition for both tools is highly dependent on specific institutional needs, reimbursement models, and negotiated pricing.

Enterprise Readiness

Lung AI

Tool A (Exo Lung AI) is part of a platform that includes secure cloud storage, DICOM/PACS/VNA integration, and workflow documentation, suggesting a more comprehensive solution for enterprise-level deployment and data management. Tool B (Reveal LINQ) primarily focuses on individual patient monitoring with data transmission to a proprietary network, which, while robust, may require more effort to integrate into broader hospital IT infrastructure beyond cardiology departments.

Innovation

Lung AI

Tool A (Exo Lung AI) demonstrates significant innovation by integrating AI directly into a handheld ultrasound device for real-time, on-device processing, enabling immediate diagnostic feedback without internet connectivity. This approach democratizes advanced imaging and AI at the point of care. While Tool B (Reveal LINQ) is innovative as a miniaturized, long-term implantable cardiac monitor with AI algorithms for false alert reduction, the core technology of implantable loop recorders has been established for a longer period.

Support & Docs

Tie

Both companies provide resources for support and documentation. Medtronic offers manuals and technical guides for Reveal LINQ, along with patient services and technical support lines. Exo provides 'Exo U' for POCUS education and training, and its website includes insights and news, suggesting a commitment to user education and ongoing information. Without more specific details on the breadth, accessibility, and responsiveness of their support channels, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung AI	Reveal LINQ
Tool Name	Lung AI	Reveal LINQ
Company	Exo	Medtronic
Description	High-performance, handheld ultrasound platform that uses artificial intelligence for imaging and therapeutic applications.	Tiny, implantable cardiac monitor that continuously records ECG for up to three years, utilizing AccuRhythmu2122 AI algorithms to accurately detect and diagnose cardiac arrhythmias.
Key Features	AI-powered detection of pleural effusion, AI-powered detection of consolidation/atelectasis, Real-time feedback and image quality monitoring (SweepAI), Automated AI-based indicators for cardiac conditions (e.g., heart failure, hypertrophy), Guided image capture for optimal scans, On-device AI processing (operates without internet), Pulsed-wave Doppler capabilities (on Exo Iris), Exo U (AI-powered POCUS education and training)	World's smallest insertable cardiac monitor (1.2 mL), Continuous ECG monitoring for up to three years, AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause), Automatic and patient-activated event recording, MRI Conditional (1.5T and 3T) with no post-insertion waiting, Minimally invasive, simplified insertion procedure, Wireless data transmission to CareLinku2122 network via MyCareLinku2122 Patient Monitor, Reveal LINQu2122 Mobile Manager app for clinician device management
Specialties	Cardiology, Emergency Medicine, Pulmonology	Cardiology, Neurology

Videos

Demos, reviews, and walkthroughs featuring Lung AI and Reveal LINQ.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Tool A (Lung AI) is integrated directly with the Exo Iris handheld ultrasound device, processing AI on-device without an internet connection, which allows for real-time feedback and image quality monitoring during scans. This on-device processing and immediate feedback could streamline point-of-care diagnostics. Tool B (Reveal LINQ) is an implantable device that transmits data wirelessly to the CareLinku2122 network via a bedside patient monitor (MyCareLinku2122), with clinicians managing the device and data through the Reveal LINQu2122 Mobile Manager app. The Medtronic CareLinku2122 network allows for remote monitoring and customized CareAlertu2122 notifications, which can be integrated into a clinic's workflow for managing patient data and alerts.

What is the accuracy and sensitivity of each tool's AI algorithms for their respective specialties?

Exo Lung AI demonstrates high accuracy for detecting pleural effusion (sensitivity 96.7%, specificity 91.2%) and consolidation/atelectasis (sensitivity 96.8%, specificity 94.5%). It also shows a sensitivity of 91% and specificity of 81% for A-line detection, and 84% sensitivity and 86% specificity for B-line detection. Medtronic's AccuRhythmu2122 AI algorithms for Reveal LINQ significantly reduce false alerts for AF (89.5% reduction) and Pause (78.4% reduction) while preserving a high percentage of true alerts (98.2% for AF, 99.9% for Pause). The LINQ family of ICMs offers a 99.7% AF detection accuracy rate.

What is the typical learning curve for physicians and supporting staff to effectively use these tools?

Exo Iris with Lung AI is designed for user-friendliness, even for non-experts, with AI assisting in image acquisition and providing real-time feedback to ensure optimal scans. This suggests a potentially lower learning curve for ultrasound interpretation. For Reveal LINQ, Medtronic provides a 'Cardiac Diagnostics Academy' with learning plans for implanters and follow-up clinicians, covering insertion procedures, patient follow-up, and remote monitoring, indicating a structured training process for effective use.

What clinical context should a physician consider when choosing between these tools?

Tool A (Lung AI) is ideal for point-of-care diagnostics in cardiology, emergency medicine, and pulmonology, helping clinicians quickly assess conditions like pleural effusion, consolidation/atelectasis, and pulmonary edema, and measure cardiac parameters such as LVEF and stroke volume. Tool B (Reveal LINQ) is suited for long-term, continuous ECG monitoring (up to three years) in cardiology and neurology, primarily for detecting and diagnosing cardiac arrhythmias like atrial fibrillation, cryptogenic stroke, and unexplained syncope, especially for patients with infrequent symptoms.

What are the security considerations beyond HIPAA for these devices, especially regarding data transmission and storage?

Exo's Lung AI operates with on-device AI processing, meaning it functions without an internet connection, which could inherently limit external data transmission vulnerabilities. For Reveal LINQ, Medtronic emphasizes dedicated protection of patient health data, with data encryption and built-in security for its mobile manager app and CareLinku2122 network, including authentication and password security, and the ability to remotely disable data flow if a tablet is lost or stolen.

Are there audit-trail features available for reviewing AI-assisted diagnoses or device data?

While specific audit-trail features for Exo Lung AI are not detailed, the system provides real-time feedback and image quality monitoring, and generates per-frame and per-clip quality scores for lung scans, which could contribute to an audit trail. For Reveal LINQ, the CareLinku2122 network generates various reports, including event reports and summary reports, and allows for customized CareAlertu2122 notifications, which inherently create a record of device activity and detected events for review.